Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Allison Berger"'
Autor:
Dennis Huszar, Allison Berger, Alejandro Gomez-Pinillos, Mi-Sook Kim, Amitkumar Mehta, Igor Proscurshim, Chirag Patel, Paolo Caimi, Bingxia Wang, Sarit Assouline, Sharon Friedlander
Publikováno v:
Blood. 134:1593-1593
Background TAK-981 is a first-in-class, small molecule inhibitor of SUMOylation, a reversible post-translational modification that regulates protein function by covalent attachment of small ubiquitin-like modifier (SUMO) proteins to a protein substra
Autor:
Thea Kalebic, Neeraj Gupta, Lillian L. Siu, John S. Kauh, David Smith, Feng Gao, Ai Min Hui, Jeffrey R. Infante, Gordana Vlahovic, Allison Berger, Jianchang Lin, John A. Thompson, Deborah Berg, Guohui Liu, Stephen Tirrell, Daniel C. Sullivan, Alessandra Di Bacco
Publikováno v:
Investigational New Drugs
SummaryPurpose Ixazomib is an investigational proteasome inhibitor with demonstrated antitumor activity in xenograft models of multiple myeloma (MM), lymphoma, and solid tumors. This open-label, phase 1 study investigated intravenous (IV) ixazomib, i
Autor:
Mitchell R. Smith, Catherine Diefenbach, Kevin R. Kelly, Andrzej Jakubowiak, Zhaowei Hua, R. Donald Harvey, Sagar Lonial, Daniel Lebovic, Bruce J. Dezube, George Mulligan, Hélène M. Faessel, Owen A. O'Connor, Jatin J. Shah, Stephen Tirrell, Robert Z. Orlowski, Allison Berger
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 22(1)
Purpose: Evaluate the safety, pharmacokinetic profile, pharmacodynamic effects, and antitumor activity of the first-in-class investigational NEDD8-activating enzyme (NAE) inhibitor pevonedistat (TAK-924/MLN4924) in patients with relapsed/refractory l
Autor:
Kristin E. Burke, Doug Bowman, Arijit Chakravarty, Mark D. Fleming, Jeffrey Ecsedy, A. A. McDonald, Vaishali Shinde, Stephen Tirrell, Stephen J. Blakemore, Allison Berger
Publikováno v:
Veterinary pathology. 51(1)
Immunohistochemistry-based biomarkers are commonly used to understand target inhibition in key cancer pathways in preclinical models and clinical studies. Automated slide-scanning and advanced high-throughput image analysis software technologies have
Autor:
Thomas J. Waldschmidt, Michael R. Acevedo, Van S. Tompkins, Ramakrishna Sompallae, Kaylia Duncan, Alicia K. Olivier, Siegfried Janz, Herbert C. Morse, Guido Tricot, Lorraine T. Tygrett, Susan A. Walsh, Allison Berger, Laura L. Boles Ponto, John Sunderland, Fenghuang Zhan, Timothy R. Rosean
Publikováno v:
Blood Cancer Journal
(18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) and computed tomography (CT) are useful imaging modalities for evaluating tumor progression and treatment responses in genetically engineered mouse models of solid human cancers, but the
Autor:
Kenneth C. Anderson, William L. Trepicchio, Alessandra Di Bacco, Hugues Bernard, Pieter Sonneveld, Allison Berger, George Mulligan, Erik Koenig, Bin Li, Jesús F. San Miguel, Sagar Lonial, Paul G. Richardson, Dixie-Lee Esseltine, Stephen J. Blakemore, David I. Lichter, Matthew C. Schu
Publikováno v:
Blood. 118:1377-1377
Abstract 1377 Background: MM is a plasma cell malignancy that remains generally incurable; however, there is significant inter-patient variation in the clinical course of MM and in survival, which is thought to relate, at least in part, to the biolog
Autor:
Peter G. Smith, James J. Garnsey, Allison Berger, George Mullligan, Bradley Stringer, Michael D. Pickard, Jie Yu, Kristin E. Burke, Doug Bowman, Alice McDonald, Mark D. Fleming
Publikováno v:
Clinical Cancer Research. 16:A31-A31
The novel small molecule MLN4924 is an inhibitor of the NEDD8 activating enzyme (NAE) and is currently in Phase I trials. As part of the ubiquitin-proteasome system, NAE is required for activity of cullin ring ligases (CRLs), a category of ubiquitin
Autor:
Karthik Venkatakrishnan, Sagar Lonial, Owen A. O'Connor, Andrzej Jakubowiak, Allison Berger, Jatin J. Shah, Peter G. Smith, George Mulligan, Robert Z. Orlowski, Alice McDonald, Lilli Petruzzelli, R. Donald Harvey, Michael D. Pickard, Molly Patterson
Publikováno v:
Blood. 114:1854-1854
Abstract 1854 Poster Board I-880 Background: MLN4924 is a first-in-class small molecule inhibitor of NEDD8-activating enzyme (NAE), an essential component of the NEDD8 conjugation pathway in the ubiquitin-proteasome system. Inhibition of NAE with MLN